Currently, institutional investors and hedge funds own approximately 77.70% of Taysha Gene Therapies' stock.

On the stock market, Taysha Gene Therapies opened at $1.76, boasting a market capitalization of $360.70 million and a P/E ratio of 2.79.

The stock has experienced volatility, fluctuating between a 12-month low of $1.19 and a high of $4.32.

Taysha Gene Therapies is focused on developing adeno-associated virus-based gene therapies aimed at treating monogenic diseases of the central nervous system, including conditions like giant axonal neuropathy and Rett syndrome.

As of January 13, 2025, research firms have issued positive forecasts for Taysha Gene Therapies, with Canaccord Genuity raising its target price from $6.00 to $8.00 while maintaining a 'buy' rating.

Additionally, Needham & Company LLC issued a 'buy' rating with a price target of $6.00 earlier this month.

Chardan Capital and Cantor Fitzgerald also reaffirmed their 'buy' ratings, setting price targets at $7.00.

After the sale, Jane Street Group LLC's ownership in Taysha Gene Therapies represented 0.05% of the company, valued at $216,000.

The consensus rating among analysts for Taysha Gene Therapies remains 'Buy' with an average price target of $6.63.

The Manufacturers Life Insurance Company notably increased its holdings by 109.0%, owning 133,213 shares valued at $298,000 after acquiring an additional 69,487 shares.

Other institutional investors have also made moves, with Bank of New York Mellon Corp acquiring a new stake worth $1,018,000 during the second quarter, while Principal Financial Group Inc. and Rhumbline Advisers purchased new positions valued at $48,000 and $413,000, respectively.

In contrast, Jane Street Group LLC reduced its stake in Taysha Gene Therapies by 16.0% during the third quarter of 2024, selling 20,552 shares and holding 107,572 shares afterward.